Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
Authors:
Open Access
- 1 January 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 99 (1) , 10-14
Abstract
In the phase I/II pediatric hydroxyurea safety trial (HUG-KIDS), school-aged children with sickle cell anemia receiving hydroxyurea at the maximally tolerated dose (MTD) had variable increases in the percentage of fetal hemoglobin (%HbF). To identify predictors of the HbF response to hydroxyurea therapy, baseline clinical and laboratory values (age, sex, hemoglobin concentration, %HbF, reticulocytes, white blood cell [WBC], platelets, and serum chemistries), as well as treatment variables (number of toxicities, noncompliance, MTD dose, and MTD blood counts) were analyzed in 53 HUG-KIDS children who achieved MTD. Baseline %HbF values (P = .001), baseline hemoglobin concentration (P = .01), MTD dose (P = .02), and compliance (P = .02) were significantly associated with a higher %HbF at MTD; in contrast, age, sex, number of toxicities, and other baseline hematologic parameters were not. After adjusting for variations in baseline %HbF, the baseline reticulocyte count (P = .05) and baseline WBC count (P = .05) were also significantly associated with a higher %HbF at MTD. Hydroxyurea-induced increases in the hemoglobin concentration and mean corpuscular volume (both higher absolute values at MTD and larger positive changes from baseline values), as well as hydroxyurea-induced decreases in reticulocytes and WBC count, were significantly associated with a higher %HbF at MTD. These data suggest that selected baseline laboratory parameters, a higher MTD dose with attention to compliance, and greater therapy-related changes in blood counts may predict the HbF response to hydroxyurea therapy for children with sickle cell anemia. The HbF response to hydroxyurea is variable and complex, however, and even children with low baseline %HbF values can develop substantial increases in %HbF at MTD.Keywords
This publication has 20 references indexed in Scilit:
- Hydroxyurea in Children with Sickle Cell DiseaseJournal of Pediatric Hematology/Oncology, 1998
- Three-Year Follow-Up of Hydroxyurea Treatment in Severely Ill Children with Sickle Cell DiseaseJournal of Pediatric Hematology/Oncology, 1997
- Clinical and hematologic effects of hydroxyurea in children with sickle cell anemiaThe Journal of Pediatrics, 1996
- Hydroxyurea therapy in children severely affected with sickle cell diseaseThe Journal of Pediatrics, 1996
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994
- A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin DisordersNew England Journal of Medicine, 1993
- Pain in Sickle Cell DiseaseNew England Journal of Medicine, 1991
- Treatment of Sickle Cell Anemia with Hydroxyurea and ErythropoietinNew England Journal of Medicine, 1990
- The relationship between fetal hemoglobin and disease severity in children with sickle cell anemiaAmerican Journal of Medical Genetics, 1987